Liprolog Mix

What Is Liprolog Mix and What Is It Used For?

Quick Answer: Liprolog Mix is a biphasic insulin lispro preparation that combines rapid-acting and intermediate-acting insulin in a single injection. It is used to treat hyperglycaemia in patients with type 1 and type 2 diabetes mellitus who require insulin therapy.

Liprolog Mix belongs to the class of biphasic insulin analogues, which are designed to mimic the body's natural insulin response to meals while also providing sustained background insulin activity. The active ingredient is insulin lispro, a recombinant human insulin analogue produced using Escherichia coli bacteria through recombinant DNA technology. Insulin lispro differs from regular human insulin by a reversal of the amino acids proline and lysine at positions B28 and B29, which allows faster absorption after subcutaneous injection compared to regular human insulin.

The biphasic formulation consists of two phases: a soluble, rapid-acting phase of insulin lispro and a crystalline, intermediate-acting phase of insulin lispro protamine suspension. The protamine-complexed insulin forms a depot at the injection site, releasing insulin gradually over several hours. This dual-phase design means that a single pre-meal injection can cover both the immediate postprandial glucose rise and the basal insulin requirements for several hours thereafter.

Liprolog Mix is indicated for the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. It is also indicated for the initial stabilisation of diabetes mellitus. The two available formulations serve different clinical needs: Liprolog Mix 25 contains 25% insulin lispro and 75% insulin lispro protamine suspension, providing a modest mealtime peak with prolonged intermediate coverage. Liprolog Mix 50 contains equal proportions of each component, offering a more pronounced mealtime peak. The choice between formulations depends on the patient's meal pattern, postprandial glucose excursions, and overall glycaemic profile.

In clinical practice, Liprolog Mix is often prescribed for patients with type 2 diabetes who are transitioning from oral antidiabetic agents alone or who need a simpler injection regimen than a full basal-bolus scheme. It may also be used in type 1 diabetes when the treating physician determines that a premixed regimen is appropriate. According to the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), premixed insulin analogues like Liprolog Mix offer improved postprandial glucose control compared to premixed human insulin preparations, with a lower risk of nocturnal hypoglycaemia.

What Should You Know Before Taking Liprolog Mix?

Quick Answer: Before starting Liprolog Mix, inform your doctor about any allergies to insulin or its excipients, all medications you take (especially other diabetes drugs and beta-blockers), and whether you are pregnant or breastfeeding. Liprolog Mix must never be administered intravenously.

Contraindications

Liprolog Mix is contraindicated in patients with known hypersensitivity to insulin lispro or any of the excipients in the formulation. These excipients include protamine sulfate, m-cresol, phenol, glycerol, dibasic sodium phosphate, zinc oxide, and water for injection. Patients who have experienced anaphylactic reactions or severe allergic reactions to insulin lispro must not use Liprolog Mix.

Liprolog Mix must not be administered intravenously. The protamine-suspended component is designed exclusively for subcutaneous injection. Intravenous administration of protamine-containing insulin suspensions can cause severe hypoglycaemia and potentially dangerous embolic events. Additionally, Liprolog Mix must not be used in insulin infusion pumps, as the suspension can clog the pump mechanism and lead to unpredictable insulin delivery.

Liprolog Mix should not be used during episodes of hypoglycaemia. If a patient's blood glucose is already low, administering additional insulin will further reduce blood glucose levels, potentially leading to severe hypoglycaemia with loss of consciousness, seizures, or death.

Warnings and Precautions

Hypoglycaemia is the most frequent adverse effect of insulin therapy and can occur if the insulin dose is too high relative to the patient's food intake and energy expenditure. Severe hypoglycaemia can lead to unconsciousness, seizures, and in extreme cases, death. Patients and caregivers should be educated on recognising and treating hypoglycaemia, including the use of glucagon emergency kits for severe episodes.

Transferring a patient from another insulin product to Liprolog Mix should be done under medical supervision, as dosage adjustments may be necessary. Factors such as the type of insulin, manufacturer, strength, species (animal, human, human insulin analogue), and method of manufacture may require dose changes. Patients switching from twice-daily conventional premixed insulin may require dose adjustment and changed timing of administration.

Illness, emotional disturbance, stress, changes in diet, and increased physical activity can all affect insulin requirements. Patients should be instructed to monitor their blood glucose more frequently during these periods and to adjust their insulin dose accordingly, in consultation with their healthcare provider. Concurrent use of thiazolidinediones (e.g., pioglitazone) with insulin may increase the risk of fluid retention and heart failure, particularly in patients with pre-existing cardiac conditions.

Pregnancy and Breastfeeding

Good glycaemic control is essential during pregnancy for the health of both mother and foetus. Insulin requirements may decrease during the first trimester and generally increase during the second and third trimesters. Careful monitoring of blood glucose is required, and dose adjustments should be made under medical supervision. Insulin lispro does not cross the placenta in clinically significant amounts based on available data.

Patients with diabetes who are breastfeeding may require adjustments in insulin dose, meal plan, or both. Insulin lispro, like other insulins, is a large peptide molecule that is degraded in the gastrointestinal tract and is therefore not expected to cause pharmacological effects in the breastfed infant. However, glycaemic control should be maintained carefully during this period, and women should discuss any concerns with their healthcare provider.

Women of childbearing potential who have diabetes should be counselled about the importance of maintaining good blood glucose control before and during pregnancy, as poorly controlled diabetes is associated with increased risks of congenital malformations, preeclampsia, macrosomia, and neonatal hypoglycaemia.

How Does Liprolog Mix Interact with Other Drugs?

Quick Answer: Several medications can enhance or diminish the blood glucose-lowering effect of Liprolog Mix. Oral antidiabetic agents, ACE inhibitors, and salicylates may increase hypoglycaemia risk, while corticosteroids, thiazide diuretics, and thyroid hormones may reduce insulin effectiveness. Always inform your doctor about all medications you are taking.

Insulin requirements may be altered by a number of substances that affect glucose metabolism. Understanding these interactions is essential for safe and effective insulin therapy. Some drugs increase the risk of hypoglycaemia by enhancing insulin's glucose-lowering effect, while others can raise blood glucose levels and necessitate an increase in insulin dose.

Drugs That May Increase Hypoglycaemia Risk

Several drug classes can potentiate the hypoglycaemic effect of insulin lispro, either by increasing insulin sensitivity, reducing hepatic glucose output, or through other pharmacological mechanisms. When these drugs are co-prescribed with Liprolog Mix, a reduction in insulin dose may be necessary, and more frequent blood glucose monitoring is advised.

Drugs That May Reduce Insulin Effectiveness

Certain medications can increase blood glucose levels, counteracting the effects of insulin therapy. When these drugs are initiated or their doses increased, an increase in Liprolog Mix dosage may be required. Conversely, dose reduction may be needed when these medications are discontinued.

What Is the Correct Dosage of Liprolog Mix?

Quick Answer: The dosage of Liprolog Mix is highly individualised and determined by your doctor based on your blood glucose levels, lifestyle, and other medications. It is typically injected subcutaneously within 15 minutes before a meal, up to two or three times daily.

There is no universal "standard" dose of Liprolog Mix. Insulin requirements vary widely between individuals and depend on factors including the type of diabetes, body weight, diet, physical activity level, kidney and liver function, and concomitant medications. The treating physician will determine the initial dose and adjust it based on self-monitored blood glucose results, HbA1c levels, and the patient's overall clinical response.

Adults

Children and Adolescents

Elderly Patients

Missed Dose

If you miss a dose of Liprolog Mix, do not take a double dose to compensate. Monitor your blood glucose level and act according to the reading. If blood glucose is elevated, contact your healthcare provider for guidance on whether to take a corrective dose. Establish a consistent routine for your injections to minimise the risk of missed doses. If you frequently miss doses, discuss simplified regimen options with your doctor.

Overdose

What Are the Side Effects of Liprolog Mix?

Quick Answer: The most common side effect of Liprolog Mix is hypoglycaemia (low blood sugar). Other possible side effects include injection site reactions, lipodystrophy, and allergic reactions. Severe allergic reactions are rare but require immediate medical attention.

Like all insulin preparations, Liprolog Mix can cause side effects, although not everybody gets them. The most clinically significant adverse effect is hypoglycaemia, which can range from mild (easily self-treated) to severe (requiring third-party assistance or hospitalisation). The frequency and severity of hypoglycaemia depend on the insulin dose, timing of injection relative to meals, physical activity, and other factors.

Patients should be thoroughly educated on the signs and symptoms of hypoglycaemia and how to manage it. Warning signs include tremor, sweating, palpitations, hunger, anxiety, confusion, visual disturbances, and difficulty concentrating. Severe hypoglycaemia may present with seizures, loss of consciousness, or coma. Risk of hypoglycaemia is increased in patients with long-standing diabetes, those with autonomic neuropathy (who may have reduced awareness of hypoglycaemia), and patients taking beta-blockers (which can mask adrenergic symptoms).

If you experience any side effects not listed here, or if any of the listed side effects become severe, contact your healthcare provider. In the European Union, you can also report side effects to your national medicines agency. Reporting helps to monitor the safety of medicines.

How Should You Store Liprolog Mix?

Quick Answer: Store unopened Liprolog Mix in a refrigerator at 2–8°C. Once in use, keep it at room temperature (below 30°C) for up to 28 days. Do not freeze. Protect from direct heat and sunlight.

Correct storage of insulin is essential to maintain its potency and safety. Improperly stored insulin may lose effectiveness, leading to poor blood glucose control without any obvious signs of degradation. Patients should be educated on proper insulin storage practices as part of their diabetes management education.

Before first use: Liprolog Mix should be stored in a refrigerator at 2–8°C (36–46°F). Keep the product in its outer carton to protect from light. Do not freeze insulin, and do not use Liprolog Mix if it has been frozen, even if it has subsequently thawed. Freezing damages the insulin molecules and disrupts the protamine-insulin complex, leading to unpredictable absorption and reduced efficacy.

After first use: Once the pen or cartridge has been opened and is in use, it can be stored at room temperature (below 30°C / 86°F) for up to 28 days. Do not return a used pen to the refrigerator. Keep the pen cap on when not in use to protect from light. After 28 days of use, discard the pen or cartridge even if it still contains insulin, as sterility and potency cannot be guaranteed beyond this period.

General precautions: Do not expose Liprolog Mix to excessive heat or direct sunlight. Do not store it near heating appliances, in cars during hot weather, or in direct sunlight on a windowsill. When travelling, carry insulin in an insulated cool bag to maintain appropriate temperature. Inspect the suspension before each use — after gentle resuspension (rolling and inverting), the insulin should appear uniformly cloudy or milky. Do not use if it remains clear, if clumps or particles are visible, or if the suspension has a frosted appearance.

Keep all medications out of the sight and reach of children. Do not use Liprolog Mix after the expiry date printed on the label and carton. Dispose of used needles in an approved sharps container and return unused or expired medications to your pharmacy for safe disposal.

What Does Liprolog Mix Contain?

Quick Answer: The active substance is insulin lispro (100 IU/mL). Excipients include protamine sulfate, m-cresol, phenol, glycerol, dibasic sodium phosphate, zinc oxide, hydrochloric acid/sodium hydroxide (for pH adjustment), and water for injection.

Understanding the full composition of your medication helps identify potential allergens and understand the role of each component. The active ingredient and each excipient in Liprolog Mix serve a specific pharmaceutical purpose.

Active substance: Insulin lispro 100 IU/mL (International Units per millilitre). Each pre-filled pen contains 300 IU of insulin lispro in 3 mL of suspension. Insulin lispro is a recombinant human insulin analogue produced by Escherichia coli using recombinant DNA technology. It has a molecular weight of approximately 5,808 daltons.

Excipients and their functions:

• Protamine sulfate — Forms a complex with insulin lispro to create the intermediate-acting suspension component. The protamine-insulin complex dissolves slowly after subcutaneous injection, providing prolonged insulin release.
• m-Cresol — Antimicrobial preservative that maintains sterility of the multi-dose preparation during the 28-day in-use period.
• Phenol — Additional antimicrobial preservative, working synergistically with m-cresol to prevent microbial contamination.
• Glycerol — Isotonicity agent that makes the injection solution isotonic with body fluids, ensuring comfortable injection and proper insulin absorption.
• Dibasic sodium phosphate — Buffer that maintains the pH of the formulation within the optimal range for insulin stability and patient comfort.
• Zinc oxide — Stabiliser that contributes to the formation of insulin hexamers, which are more stable than monomeric insulin and ensure product shelf-life.
• Hydrochloric acid and/or sodium hydroxide — pH adjusters used during manufacture to achieve the target pH (approximately 7.0–7.8).
• Water for injection — Solvent.

Patients with known allergies to any of the excipients should inform their healthcare provider before starting Liprolog Mix. Protamine sulfate, in particular, may rarely cause allergic reactions in sensitised individuals, including those with prior exposure to protamine-containing medications (such as NPH insulin or protamine used to reverse heparin anticoagulation).